// App-Quantinova.ai

DOP60 : The interleukin 22 transcriptional programme is activated in human colonic inflammation and associated to anti-TNFα primary non-response in Crohn’s

Researchers

Presenter

  • P Pavlidis

Principal Investigators

  • A Tsakmaki

  • U Niazi

  • J Digby-Bell

  • G Lombardi

  • B Hayee

  • G Bewick

  • N Powell

Medical Centers

  • Kings College London, London, UK

  • BRC Bioinformatics core, London, UK

  • Kings College Hospital, London,

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Interferon-gamma

  • Interleukin 17A

  • Interleukin-22

Drug/Treatment

  • Interleukin

  • Interferon Gamma

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved